Literature DB >> 29859750

Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.

Jiangying Cao1, Chunhua Ma2, Jie Zang1, Shuai Gao1, Qianwen Gao1, Xiujie Kong1, Yugang Yan1, Xuewu Liang1, Qin'ge Ding1, Chunlong Zhao1, Binghe Wang3, Wenfang Xu1, Yingjie Zhang4.   

Abstract

The over-expression of aminopeptidase N on diverse malignant cells is associated with the tumor angiogenesis and metastasis. In this report, one new series of leucine ureido derivatives containing the triazole moiety was designed, synthesized and evaluated as APN inhibitors. Among them, compound 13v showed the best APN inhibition with an IC50 value of 0.089 ± 0.007 μM, which was two orders of magnitude lower than that of bestatin (IC50 = 9.4 ± 0.5 μM). Compound 13v also showed dose-dependent anti-angiogenesis activities. Even at the lower concentration (10 μM), compound 13v presented similar anti-angiogenesis activity compared with bestatin at 100 μM in both the human umbilical vein endothelial cells (HUVECs) capillary tube formation assay and the rat thoracic aorta rings test. Moreover, compared with bestatin, 13v exhibited comparable, if not better in vivo anti-metastasis activity in a mouse H22 pulmonary metastasis model.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Aminopeptidase N; Anti-angiogenesis; Anti-metastasis; CD13; Triazole

Mesh:

Substances:

Year:  2018        PMID: 29859750     DOI: 10.1016/j.bmc.2018.04.041

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.

Authors:  Qian Liu; Hang Dong; Wei Zhao; Guozhen Zhang; Shunda Li; Qifu Xu; Yingjie Zhang
Journal:  ACS Med Chem Lett       Date:  2021-11-10       Impact factor: 4.345

Review 2.  1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.

Authors:  Khurshed Bozorov; Jiangyu Zhao; Haji A Aisa
Journal:  Bioorg Med Chem       Date:  2019-07-04       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.